Vaxil Bio Ltd.
VXLLF
$0.11
$0.00-1.63%
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -37.12% | 148.10% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -37.12% | 148.10% | |||
| Operating Income | 37.12% | -148.10% | |||
| Income Before Tax | 41.35% | -118.91% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 41.35% | -118.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 41.35% | -118.81% | |||
| EBIT | 37.12% | -148.10% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 41.45% | -114.73% | |||
| Normalized Basic EPS | 41.32% | -83.33% | |||
| EPS Diluted | 41.45% | -114.73% | |||
| Normalized Diluted EPS | 41.32% | -83.33% | |||
| Average Basic Shares Outstanding | 0.00% | 27.64% | |||
| Average Diluted Shares Outstanding | 0.00% | 27.64% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||